Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 322 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemophilia A, Congenital Clear all
Completed Phase 3 Interventional Results available

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

NCT03569891
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional Results available

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

NCT02695160
View directory record Official record
Conditions
Hemophilia B
Interventions
SB-FIX
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease

NCT00212485
View directory record Official record
Conditions
Inherited Bleeding Disorders
Interventions
Power Doppler Sonography, MRI
Procedure
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
1 Year to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2010 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

NCT01992549
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Human-cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 18, 2026, 6:24 AM EDT
Withdrawn Early Phase 1 Interventional

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

NCT06345833
View directory record Official record
Conditions
Hemophilia, Hemorrhage, Facelift Surgery
Interventions
1%Tranexamic acid with standard local, 3% TXA, 1% TXA with local plus 3% TXA-soaked pledgets
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

BAX 855 Continuation

NCT01945593
View directory record Official record
Conditions
Hemophilia A
Interventions
BAX855
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
21
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

NCT00364182
View directory record Official record
Conditions
Hemophilia B
Interventions
Recombinant Coagulation Factor IX (BeneFIX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Chicago, Illinois • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 18, 2026, 6:24 AM EDT
Not listed Phase 3 Interventional

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

NCT01619046
View directory record Official record
Conditions
Hemophilia A
Interventions
GreenGene™ F and an approved recombinant Factor VIII product, GreenGene™ F
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

NCT01561924
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
16 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Berkeley, California • Los Angeles, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 6:24 AM EDT
Completed No phase listed Observational

Handheld Ultrasound (HHUS) for Home Use in Hemophilia

NCT04131920
View directory record Official record
Conditions
Joint Bleed, Hemophilia A
Interventions
handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Device
Lead sponsor
Washington Institute for Coagulation
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

NCT02020369
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
12 Years to 75 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321
View directory record Official record
Conditions
Hemophilia A or B
Interventions
PF-06741086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 18, 2026, 6:24 AM EDT
Recruiting Phase 4 Interventional

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT02053792
View directory record Official record
Conditions
Hemophilia B
Interventions
rIX-FP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 70 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 18, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Alphanate in Immune Tolerance Induction Therapy

NCT03095287
View directory record Official record
Conditions
Hemophilia A, Congenital
Interventions
Alphanate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 18, 2026, 6:24 AM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385
View directory record Official record
Conditions
Hemophilia A
Interventions
single blood draw
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • New Hyde Park, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 18, 2026, 6:24 AM EDT
Terminated Phase 4 Interventional

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673
View directory record Official record
Conditions
Hemophilia A
Interventions
Kogenate (BAY 14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Detroit, Michigan • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 18, 2026, 6:24 AM EDT
Active, not recruiting No phase listed Observational

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934
View directory record Official record
Conditions
Hemophilia A
Interventions
ADYNOVI/ADYNOVATE
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 18, 2026, 6:24 AM EDT
Completed Phase 3 Interventional

A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

NCT00001104
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 6:24 AM EDT